Acadia Healthcare Co. (NASDAQ:ACHC) issued an update on its third quarter earnings guidance on Tuesday morning. The company provided EPS guidance of ~$0.58 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.66. The company issued revenue guidance of ~$735 million, compared to the consensus revenue estimate of $744.43 million.
Shares of Acadia Healthcare Co. (NASDAQ:ACHC) opened at 45.19 on Wednesday. Acadia Healthcare Co. has a 12-month low of $42.47 and a 12-month high of $74.77. The firm has a market capitalization of $3.95 billion, a P/E ratio of 24.14 and a beta of 0.86. The company has a 50-day moving average price of $49.05 and a 200-day moving average price of $54.52.
Acadia Healthcare (NASDAQ:ACHC) last released its quarterly earnings data on Friday, July 29th. The company reported $0.73 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.73. Acadia Healthcare had a net margin of 6.44% and a return on equity of 9.35%. The business earned $756.50 million during the quarter, compared to analyst estimates of $752.57 million. During the same period in the previous year, the business earned $0.57 EPS. Acadia Healthcare’s revenue was up 66.8% compared to the same quarter last year. Equities analysts predict that Acadia Healthcare Co. will post $2.63 EPS for the current year.
A number of research firms recently weighed in on ACHC. Zacks Investment Research lowered shares of Acadia Healthcare from a hold rating to a sell rating in a research note on Monday, July 11th. RBC Capital Markets reissued an outperform rating and issued a $78.00 price target (down from $86.00) on shares of Acadia Healthcare in a report on Monday, August 1st. Robert W. Baird cut their price target on shares of Acadia Healthcare from $67.00 to $66.00 and set an outperform rating for the company in a report on Thursday, September 15th. JPMorgan Chase & Co. reissued a hold rating and issued a $61.00 price target on shares of Acadia Healthcare in a report on Tuesday, September 27th. Finally, Leerink Swann reissued an outperform rating and issued a $80.00 price target on shares of Acadia Healthcare in a report on Monday, September 26th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $77.21.
In other Acadia Healthcare news, CFO David M. Duckworth sold 16,670 shares of the business’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $54.33, for a total value of $905,681.10. Following the completion of the sale, the chief financial officer now directly owns 11,688 shares of the company’s stock, valued at $635,009.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Waud Capital Partners Iii, L.L sold 457,443 shares of the business’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $48.39, for a total transaction of $22,135,666.77. The disclosure for this sale can be found here. 17.20% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the company. Woodmont Investment Counsel LLC increased its stake in Acadia Healthcare by 4.3% in the second quarter. Woodmont Investment Counsel LLC now owns 18,123 shares of the company’s stock valued at $1,004,000 after buying an additional 745 shares in the last quarter. American International Group Inc. increased its stake in Acadia Healthcare by 71.7% in the second quarter. American International Group Inc. now owns 2,218 shares of the company’s stock valued at $123,000 after buying an additional 926 shares in the last quarter. Raymond James & Associates increased its stake in Acadia Healthcare by 3.5% in the second quarter. Raymond James & Associates now owns 46,025 shares of the company’s stock valued at $2,550,000 after buying an additional 1,539 shares in the last quarter. Atlantic Trust Group LLC increased its stake in Acadia Healthcare by 1.5% in the second quarter. Atlantic Trust Group LLC now owns 125,863 shares of the company’s stock valued at $6,972,000 after buying an additional 1,909 shares in the last quarter. Finally, US Bancorp DE increased its stake in Acadia Healthcare by 9.1% in the second quarter. US Bancorp DE now owns 29,101 shares of the company’s stock valued at $1,612,000 after buying an additional 2,431 shares in the last quarter.
Acadia Healthcare Company Profile
Acadia Healthcare Company, Inc is a provider of behavioral healthcare services. The Company operates in two segments: U.S. Facilities and U.K. Facilities. The Company develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities and facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities throughout the United States, the United Kingdom and Puerto Rico.
Receive News & Ratings for Acadia Healthcare Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare Co. and related companies with MarketBeat.com's FREE daily email newsletter.